[1]
|
Vaughan, S., Coward, J.I., Bast, R.C.J., Berchuck, A., Berek, J.S., Brenton, J.D., Coukos, G., Crum, C.C., Drapkin, R., Etemadmoghadam, D., Friedlander, M., Gabra, H., Kaye, S.B., Lord, C.J., Lengyel, E., Levine, D.A., McNeish, I.A., Menon, U., Mills, G.B., Nephew, K.P., Oza, A.M., Sood, A.K., Stronach, E.A., Walczak, H., Bowtell, D.D. and Balkwill, F.R. (2011) Rethinking Ovarian Cancer: Recommendations for Improving Outcomes. Nature Reviews Cancer, 11, 719-725. https://doi.org/10.1038/nrc3144
|
[2]
|
Chang, S.-J. and Bristow, R.E. (2012) Evolution of Surgical Treatment Paradigms for Advanced-Stage Ovarian Cancer: Redefining “Optimal” Residual Disease. Gynecologic Oncology, 125, 483-492. https://doi.org/10.1016/j.ygyno.2012.02.024
|
[3]
|
Vergote, I., Tropé, C.G., Amant, F., Kristensen, G.B., Ehlen, T., Johnson, N., Verheijen, R.H.M., van der Burg, M.E.L., Lacave, A.J., Panici, P.B., Kenter, G.G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G.C.E., Pecorelli, S. and Reed, N.S. (2010) Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. The New England Journal of Medicine, 363, 943-953. https://doi.org/10.1056/NEJMoa0908806
|
[4]
|
Fagotti, A., Ferrandina, M.G., Vizzielli, G., Pasciuto, T., Fanfani, F., Gallotta, V., Margariti, P.A., Chiantera, V., Costantini, B., Gueli Alletti, S., Cosentino, F. and Scambia, G. (2020) Randomized Trial of Primary Debulking Surgery versus Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer, 30, 1657-1664. https://doi.org/10.1136/ijgc-2020-001640
|
[5]
|
Kehoe, S., Hook, J., Nankivell, M., Jayson, G.C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., Dobbs, S., Essapen, S., Twigg, J., Herod, J., McCluggage, G., Parmar, M. and Swart, A.-M. (2015) Primary Chemotherapy versus Primary Surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Randomised, Controlled, Non-Inferiority Trial. The Lancet, 386, 249-257. https://doi.org/10.1016/S0140-6736(14)62223-6
|
[6]
|
Colombo, N., Sessa, C., Bois, A.du; Ledermann, J., McCluggage, W.G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F. and Querleu, D. (2019) ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease. Annals of Oncology, 30, 672-705. https://doi.org/10.1136/ijgc-2019-000308
|
[7]
|
Bohm, S., Faruqi, A., Said, I., Lockley, M., Brockbank, E., Jeyarajah, A., Fitzpatrick, A., Ennis, D., Dowe, T., Santos, J.L., Cook, L.S., Tinker, A.V., Le, N.D., Gilks, C.B. and Singh, N. (2015) Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. Journal of Clinical Oncology, 33, 2457-2463. https://doi.org/10.1200/JCO.2014.60.5212
|
[8]
|
Santoro, A., Angelico, G., Piermattei, A., Inzani, F., Valente, M., Arciuolo, D., Spadola, S., Mulè, A., Zorzato, P., Fagotti, A., Scambia, G. and Zannoni, G.F. (2019) Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease. Frontiers in Oncology, 9, Article No. 778. https://doi.org/10.3389/fonc.2019.00778
|
[9]
|
Lawson, B.C., Euscher, E.D., Bassett, R.L., Liu, J., Ramalingam, P., Zhong, Y., Fleming, N.D. and Malpica, A. (2020) A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-Grade Serous Carcinoma: Is It Clinically Relevant? The American Journal of Surgical Pathology, 44, 206-213. https://doi.org/10.1097/PAS.0000000000001391
|
[10]
|
Santoro, A., Travaglino, A., Inzani, F., Straccia, P., Arciuolo, D., Valente, M., D’Alessandris, N., Scaglione, G., Angelico, G., Piermattei, A., Cianfrini, F., Raffone, A. and Zannoni, G.F. (2022) Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis. Diagnostics (Basel, Switzerland), 12, Article No. 633. https://doi.org/10.3390/diagnostics12030633
|
[11]
|
Angelico, G., Caltabiano, R., Loreto, C., Ieni, A., Tuccari, G., Ledda, C. and Rapisarda, V. (2018) Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report. International Journal of Molecular Sciences, 19, Article No. 685. https://doi.org/10.3390/ijms19030685
|
[12]
|
Chen, D.S. and Mellman, I. (2017) Elements of Cancer Immunity and the Cancer-Immune Set Point. Nature, 541, 321-330. https://doi.org/10.1038/nature21349
|
[13]
|
Goode, E.L., Block, M.S., Kalli, K.R., Vierkant, R.A., Chen, W., Fogarty, Z.C., Gentry-Maharaj, A., Toloczko, A., Hein, A., Bouligny, A.L., Jensen, A., Osorio, A., Hartkopf, A., Ryan, A., Chudecka-Glaz, A., Magliocco, A.M., Hartmann, A., Jung, A.Y., Gao, B., Hernandez, B.Y., Fridley, B.L., McCauley, B.M., Kennedy, C.J., Wang, C., Karpinskyj, C., De Sousa, C.B., Tiezzi, D.G., Wachter, D.L., Herpel, E., Taran, F.A., Modugno, F., Nelson, G., Lubiński, J., Menkiszak, J., Alsop, J., Lester, J., García-Donas, J., Nation, J., Hung, J., Palacios, J., Rothstein, J.H., Kelley, J.L., De Andrade, J.M., Robles-Díaz, L., Intermaggio, M.P., Widschwendter, M., Beckmann, M.W., Ruebner, M., Jimenez-Linan, M., Singh, N., Oszurek, O., Harnett, P.R., Rambau, P.F., Sinn, P., Wagner, P., Ghatage, P., Sharma, R., Edwards, R.P., Ness, R.B., Orsulic, S., Brucker, S.Y., Johnatty, S.E., Longacre, T.A., Ursula, E., McGuire, V., Sieh, W., Natanzon, Y., Li, Z., Whittemore, A.S., Anna, deFazio; Staebler, A., Karlan, B.Y., Gilks, B., Bowtell, D.D., Hogdall, E., Candido Dos Reis, F.J., Steed, H., Campbell, I.G., Gronwald, J., Benítez, J., Koziak, J.M., Chang-Claude, J., Moysich, K.B., Kelemen, L.E., Cook, L.S., Goodman, M.T., García, M.J., Fasching, P.A., Kommoss, S., Deen, S., Kjaer, S.K., Menon, U., Brenton, J.D., Pharoah, P.D., Chenevix-Trench, G., Huntsman, D.G., Winham, S.J., Kobel, M. and Ramus, S.J. (2017) Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 3, e173290. https://doi.org/10.1001/jamaoncol.2017.3290
|
[14]
|
Clarke, B., Tinker, A.V., Lee, C.-H., Subramanian, S., Van de Rijn, M., Turbin, D., Kalloger, S., Han, G., Ceballos, K., Cadungog, M.G., Huntsman, D.G., Coukos, G. and Gilks, C.B. (2009) Intraepithelial T Cells and Prognosis in Ovarian Carcinoma: Novel Associations with Stage, Tumor Type, and BRCA1 Loss. Modern Pathology, 22, 393-402. https://doi.org/10.1038/modpathol.2008.191
|
[15]
|
Mariya, T., Hirohashi, Y., Torigoe, T., Asano, T., Kuroda, T., Yasuda, K., Mizuuchi, M., Sonoda, T., Saito, T. and Sato, N. (2014) Prognostic Impact of Human Leukocyte Antigen Class I Expression and Association of Platinum Resistance with Immunologic Profiles in Epithelial Ovarian Cancer. Cancer Immunology Research, 2, 1220-1229. https://doi.org/10.1158/2326-6066.CIR-14-0101
|
[16]
|
Pellegrino, B., Mateo, J., Serra, V. and Balmana, J. (2019) Controversies in Oncology: Are Genomic Tests Quantifying Homologous Recombination Repair Deficiency (HRD) Useful for Treatment Decision Making? ESMO Open, 4, e000480. https://doi.org/10.1136/esmoopen-2018-000480
|
[17]
|
Miller, R.E., Leary, A., Scott, C.L., Serra, V., Lord, C.J., Bowtell, D., Chang, D.K., Garsed, D.W., Jonkers, J., Ledermann, J.A., Nik-Zainal, S., Ray-Coquard, I., Shah, S.P., Matias-Guiu, X., Swisher, E.M. and Yates, L.R. (2020) ESMO Recommendations on Predictive Biomarker Testing for Homologous Recombination Deficiency and PARP Inhibitor Benefit in Ovarian Cancer. Annals of Oncology, 31, 1606-1622. https://doi.org/10.1016/j.annonc.2020.08.2102
|
[18]
|
Tew, W.P., Lacchetti, C., Ellis, A., Maxian, K., Banerjee, S., Bookman, M., Jones, M.B., Lee, J.-M., Lheureux, S., Liu, J.F., Moore, K.N., Muller, C., Rodriguez, P., Walsh, C., Westin, S.N. and Kohn, E.C. (2020) PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 38, 3468-3493. https://doi.org/10.1200/JCO.20.01924
|
[19]
|
Xu, K., Yang, S. and Zhao, Y. (2017) Prognostic Significance of BRCA Mutations in Ovarian Cancer: An Updated Systematic Review with Meta-Analysis. Oncotarget, 8, 285-302. https://doi.org/10.18632/oncotarget.12306
|
[20]
|
Gorodnova, T.V., Sokolenko, A.P., Ivantsov, A.O., Iyevleva, A.G., Suspitsin, E.N., Aleksakhina, S.N., Yanus, G.A., Togo, A.V., Maximov, S.Y. and Imyanitov, E.N. (2015) High Response Rates to Neoadjuvant Platinum-Based Therapy in Ovarian Cancer Patients Carrying Germ-Line BRCA Mutation. Cancer Letters, 369, 363-367. https://doi.org/10.1016/j.canlet.2015.08.028
|
[21]
|
Estati, F.L., Alencar, V., Pirolli, R., Ribeiro, A.R.G., Torrezan, G.T., Carraro, D.M., Formiga, M.N., Guimaraes, A.P., Baiocchi, G. and Costa, A.A.B.A.D. (2020) Influence of BRCA Pathogenic Variants in the Benefit of Secondary Cytoreductive Surgery. Journal of Clinical Oncology, 38, 6076-6076. https://doi.org/10.1200/JCO.2020.38.15_suppl.6076
|
[22]
|
Coleman, R.L., Spirtos, N.M., Enserro, D., Herzog, T.J., Sabbatini, P., Armstrong, D.K., Kim, J.-W., Park, S.-Y., Kim, B.-G., Nam, J.-H., Fujiwara, K., Walker, J.L., Casey, A.C., Alvarez Secord, A., Rubin, S., Chan, J.K., DiSilvestro, P., Davidson, S.A., Cohn, D.E., Tewari, K.S., Basen-Engquist, K., Huang, H.Q., Brady, M.F. and Mannel, R.S. (2019) Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. The New England Journal of Medicine, 381, 1929-1939. https://doi.org/10.1056/NEJMoa1902626
|
[23]
|
Lord, C.J. and Ashworth, A. (2017) PARP Inhibitors: Synthetic Lethality in the Clinic. Science, 355, 1152-1158. https://doi.org/10.1126/science.aam7344
|
[24]
|
Blanc-Durand, F., Tang, R., Pommier, M., Nashvi, M., Cotteret, S., Genestie, C., Le Formal, A., Pautier, P., Michels, J., Kfoury, M., Hervé, R., Mengue, S., Wafo, E., Elies, A., Miailhe, G., Uzan, J., Rouleau, E. and Leary, A. (2023) Clinical Relevance of BRCA1 Promoter Methylation Testing in Ovarian Cancer Patients. Clinical Cancer Research, 29, 3124-3129. https://doi.org/10.1158/1078-0432.CCR-22-3328
|
[25]
|
Takamatsu, S., Yoshihara, K., Baba, T., Shimada, M., Yoshida, H., Kajiyama, H., Oda, K., Mandai, M., Okamoto, A., Enomoto, T. and Matsumura, N. (2023) Prognostic Relevance of HRDness Gene Expression Signature in Ovarian High-Grade Serous Carcinoma; JGOG3025-TR2 Study. British Journal of Cancer, 128, 1095-1104. https://doi.org/10.1038/s41416-022-02122-9
|
[26]
|
Blanc-Durand, F., Yaniz-Galende, E., Llop-Guevara, A., Genestie, C., Serra, V., Herencia-Ropero, A., Klein, C., Berton, D., Lortholary, A., Dohollou, N., Desauw, C., Fabbro, M., Malaurie, E., Bonichon-Lamaichhane, N., Dubot, C., Kurtz, J.E., de Rauglaudre, G., Raban, N., Chevalier-Place, A., Ferron, G., Kaminsky, M.-C., Kramer, C., Rouleau, E. and Leary, A. (2023) A RAD51 Functional Assay as a Candidate Test for Homologous Recombination Deficiency in Ovarian Cancer. Gynecologic Oncology, 171, 106-113. https://doi.org/10.1016/j.ygyno.2023.01.026
|
[27]
|
Rustin, G.J.S., Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I., Cervantes, A. and Vermorken, J. (2004) Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer). JNCI: Journal of the National Cancer Institute, 96, 487-488. https://doi.org/10.1093/jnci/djh081
|
[28]
|
Lee, C.K., Michael, F., Chris, B., Gebski, V.J., Alexander, G., Ignace, V., Sandro, P., Nicoletta, D., Barbara, S. and Delva, R. (2011) Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. JNCI: Journal of the National Cancer Institute, 103, 1338-1342. https://doi.org/10.1093/jnci/djr282
|
[29]
|
Coleman, R.L., Gordon, A., Barter, J., Sun, S., Rackoff, W. and Herzog, T.J. (2007) Early Changes in CA125 after Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients. The Oncologist, 12, 72-78. https://doi.org/10.1634/theoncologist.12-1-72
|
[30]
|
You, B., Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Varsellona, N., Emons, G., Rehman, K., Steffensen, K.D., Reinthaller, A., Pujade-Lauraine, E. and Oza, A. (2013) The Strong Prognostic Value of KELIM, A Model-Based Parameter from CA 125 Kinetics in Ovarian Cancer: Data from CALYPSO Trial (a GINECO-GCIG Study). Gynecologic Oncology, 130, 289-294. https://doi.org/10.1016/j.ygyno.2013.05.013
|
[31]
|
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P.A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., Sehouli, J., Lortholary, A., Kristensen, G., Jackisch, C., Joly, F., Brown, C., Le Fur, N. and Du Bois, A. (2010) Pegylated Liposomal Doxorubicin and Carboplatin Compared with Paclitaxel and Carboplatin for Patients with Platinum-Sensitive Ovarian Cancer in Late Relapse. Journal of Clinical Oncology, 28, 3323-3329. https://doi.org/10.1200/JCO.2009.25.7519
|
[32]
|
Colomban, O., Tod, M., Leary, A., Ray-Coquard, I., Lortholary, A., Hardy-Bessard, A.C., Pfisterer, J., Du Bois, A., Kurzeder, C., Burges, A., Péron, J., Freyer, G. and You, B. (2019) Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. Clinical Cancer Research, 25, 5342-5350. https://doi.org/10.1158/1078-0432.CCR-18-3335
|
[33]
|
You, B., Robelin, P., Tod, M., Louvet, C., Lotz, J.-P., Abadie-Lacourtoisie, S., Fabbro, M., Desauw, C., Bonichon-Lamichhane, N., Kurtz, J.-E., Follana, P., Leheurteur, M., Piano, F.D., Ferron, G., De Rauglaudre, G., Ray-Coquard, I., Combe, P., Chevalier-Place, A., Joly, F., Leary, A., Pujade-Lauraine, E., Freyer, G. and Colomban, O. (2020) CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clinical Cancer Research, 26, 4625-4632. https://doi.org/10.1158/1078-0432.CCR-20-0054
|
[34]
|
You, B., Van Wagensveld, L., Tod, M., Sonke, G.S., Kruitwagen, R., Du Bois, A., Selle, F., Perren, T.J., Pfisterer, J., Joly, F., Cook, A., Kaminsky-Forrett, M.-C., Wollschlaeger, K., Lortholary, A., Tome, O., Leary, A., Freyer, G., Van Der Aa, M. and Colomban, O. (2020) 815MO the Impact of Chemosensitivity Assessed by Modeled CA-125 KELIM on the Likelihood of Long Progression-Free Survivorship (PS) after 1st Line Treatment in Ovarian Cancer: An Analysis of 4,450 Patients. Annals of Oncology, 31, S616. https://doi.org/10.1016/j.annonc.2020.08.954
|
[35]
|
Colomban, O., Tod, M., Leary, A., Ray-Coquard, I.L., Lortholary, A., Hardy-Bessard, A.-C., Pfisterer, J., Du Bois, A., Kurzeder, C., Burges, A., Peron, J., Freyer, G. and You, B. (2019) Early Prediction of the Platinum-Resistant Relapse Risk Using the CA125 Modeled Kinetic Parameter KELIM: A Pooled Analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/MRC CTU/GCIG Trials). Annals of Oncology, 30, v419. https://doi.org/10.1093/annonc/mdz250.035
|
[36]
|
You, B., Clamp, A., Cook, A., McNeish, I. and Colomban, O. (2022) Differential Benefit from Fractionated Dose-Dense First-Line Chemotherapy for Epithelial Ovarian Cancer (EOC) According to Kelim-Evaluated Tumour Primary Chemosensitivity: Exploratory Analysis of Icon-8 Trial. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.4043678
|
[37]
|
Onda, T., Satoh, T., Ogawa, G., Saito, T., Kasamatsu, T., Nakanishi, T., Mizutani, T., Takehara, K., Okamoto, A., Ushijima, K., Kobayashi, H., Kawana, K., Yokota, H., Takano, M., Kanao, H., Watanabe, Y., Yamamoto, K., Yaegashi, N., Kamura, T. and Yoshikawa, H. (2020) Comparison of Survival between Primary Debulking Surgery and Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal and Peritoneal Cancers in Phase III Randomised Trial. European Journal of Cancer, 130, 114-125. https://doi.org/10.1016/j.ejca.2020.02.020
|
[38]
|
Vergote, I., Coens, C., Nankivell, M., et al. (2018) Neoadjuvant Chemotherapy versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data from the EORTC 55971 and CHORUS Trials. The Lancet Oncology, 19, 1680-1687. https://doi.org/10.1016/S1470-2045(18)30566-7
|
[39]
|
Chang, S.-J., Hodeib, M., Chang, J. and Bristow, R.E. (2013) Survival Impact of Complete Cytoreduction to No Gross Residual Disease for Advanced-Stage Ovarian Cancer: A Meta-Analysis. Gynecologic Oncology, 130, 493-498. https://doi.org/10.1016/j.ygyno.2013.05.040
|
[40]
|
Elattar, A., Bryant, A., Winter-Roach, B.A., Hatem, M. and Naik, R. (2011) Optimal Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer. Cochrane Database of Systematic Reviews, No. 9, CD007565. https://doi.org/10.1002/14651858.CD007565.pub2
|
[41]
|
You, B., Sehgal, V., Hosmane, B., Huang, X., Ansell, P.J., Dinh, M.H., Bell-McGuinn, K., Luo, X., Fleming, G.F., Friedlander, M., Bookman, M.A., Moore, K.N., Steffensen, K.D., Coleman, R.L. and Swisher, E.M. (2023) CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis from the VELIA/GOG-3005 Study. Journal of Clinical Oncology, 41, 107-116. https://doi.org/10.1200/JCO.22.00430
|
[42]
|
Van Wagensveld, L., Colomban, O., Van Der Aa, M., Tod, M., Sonke, G.S., Kruitwagen, R. and You, B. (2020) 847P the Prognostic Value of Chemosensitivity, Estimated by the Modeled CA-125 KELIM, In Ovarian Cancer Patients Treated with Neo-Adjuvant Chemotherapy in the Netherlands. Annals of Oncology, 31, S633. https://doi.org/10.1016/j.annonc.2020.08.986
|
[43]
|
Colomban, O., Clamp, A., Cook, A., McNeish, I.A. and You, B. (2023) Benefit from Fractionated Dose-Dense Chemotherapy in Patients with Poor Prognostic Ovarian Cancer: ICON-8 Trial. JCO Clinical Cancer Informatics, 7, e2200188. https://doi.org/10.1200/CCI.22.00188
|
[44]
|
Perren, T.J., Swart, A.M., Pfisterer, J., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., Carey, M.S., Beale, P., Cervantes, A., Kurzeder, C., Du Bois, A., Sehouli, J., Kimmig, R., Stahle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M.R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M.K.B., Oza, A.M. and ICON7 Investigators (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. The New England Journal of Medicine, 365, 2484-2496. https://doi.org/10.1056/NEJMoa1103799
|
[45]
|
Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., Mannel, R.S., Homesley, H.D., Fowler, J., Greer, B.E., Boente, M., Birrer, M.J., Liang, S.X. and Gynecologic Oncology Group (2011) Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. The New England Journal of Medicine, 365, 2473-2483. https://doi.org/10.1056/NEJMoa1104390
|
[46]
|
Tewari, K.S., Burger, R.A., Enserro, D., Norquist, B.M., Swisher, E.M., Brady, M.F., Bookman, M.A., Fleming, G.F., Huang, H., Homesley, H.D., Fowler, J.M., Greer, B.E., Boente, M., Liang, S.X., Ye, C., Bais, C., Randall, L.M., Chan, J.K., Ferriss, J.S., Coleman, R.L., Aghajanian, C., Herzog, T.J., DiSaia, P.J., Copeland, L.J., Mannel, R.S., Birrer, M.J. and Monk, B.J. (2019) Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. Journal of Clinical Oncology, 37, 2317-2328. https://doi.org/10.1200/JCO.19.01009
|
[47]
|
Oza, A.M., Cook, A.D., Pfisterer, J., Embleton, A., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., Carey, M.S., Beale, P., Cervantes, A., Park-Simon, T.-W., Rustin, G., Joly, F., Mirza, M.R., Plante, M., Quinn, M., Poveda, A., Jayson, G.C., Stark, D., Swart, A.M., Farrelly, L., Kaplan, R., Parmar, M.K.B., Perren, T.J. and ICON7 Trial Investigators (2015) Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial. The Lancet Oncology, 16, 928-936. https://doi.org/10.1016/S1470-2045(15)00086-8
|
[48]
|
Colomban, O., Tod, M., Peron, J., Perren, T.J., Leary, A., Cook, A.D., Sajous, C., Freyer, G. and You, B. (2020) Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectrum, 4, pkaa026. https://doi.org/10.1093/jncics/pkaa026
|
[49]
|
Hannaway, N., Kassaris, S., Davies, J.M., Smrke, A., Tinker, A. and Drew, Y. (2023) Using Chemotherapy Response by KELIM Score to Predict Response to First Line Maintenance PARP Inhibitor Therapy in Non-BRCA Mutant/Homologous Recombination Deficiency (HRD) Unknown High Grade Serous Ovarian Cancer (HGSOC). Journal of Clinical Oncology, 41, e17547. https://doi.org/10.1200/JCO.2023.41.16_suppl.e17547
|
[50]
|
Colomban, O., Swisher, E.M., Kristeleit, R., McNeish, I., Shapira-Frommer, R., Goble, S., Lin, K.K., Maloney, L., Freyer, G. and You, B. (2023) Mathematical Modeling of the Early Modeled CA-125 Longitudinal Kinetics (KELIM-PARP) as a Pragmatic Indicator of Rucaparib Efficacy in Patients with Recurrent Ovarian Carcinoma in ARIEL2 & STUDY 10. EBioMedicine, 89, Article ID: 104477. https://doi.org/10.1016/j.ebiom.2023.104477
|